BMC Microbiology

Table 4 Cumulative MFC profile of 65 clinical isolates of Candida spp. treated with 20-piperidin-2-yl-5α-pregnan-3β,20-diol (AZA) and 24(R,S),25-epiminolanosterol (EIL).

From: Growth inhibition and ultrastructural alterations induced by Δ²⁴⁽²⁵⁾-sterol methyltransferase inhibitors in Candida spp. isolates, including non-albicans organisms

		Cumulative MFC* (μg.ml^-1)
Species (no. isolates)	Drugs	0.03	1	2	4	8	16	> 16
All species (65)	AZA	1.52	3.04	12.16	16.72	34.96	44.08	100
	EIL			6.08	15.20	30.40	51.68	100
Candida albicans (21)	AZA			4.76	4.76	9.52	9.52	100
	EIL				9.52	28.57	61.98	100
Candida parapsilosis (19)	AZA		5.26	26.31	36.87	68.42	68.42	100
	EIL			10.52	15.79	26.31	63.15	100
Candida tropicalis (14)	AZA					35.71	64.28	100
	EIL			7.17	7.17	35.71	42.87	100
Candida glabrata (2)	AZA			50	50	50	50	100
	EIL				50	50	50	100
Candida krusei (1)	AZA							100
	EIL							100
Candida lusitaneae (1)	AZA							100
	EIL				100	100	100	100
Candida guilliermondii (3)	AZA							100
	EIL							100
Candida zeylanoides (1)	AZA	100	100	100	100	100	100	100
	EIL			100	100	100	100	100
Candida rugosa (1)	AZA				100	100	100	100
	EIL							100

* data is expressed in percentual of isolates.

Back to article page

ISSN: 1471-2180

Contact us

General enquiries: journalsubmissions@springernature.com